Cell signalling
Which STAT partners dominate cancer signaling networks?
Open access · cc by · source: Europe PMC
An IID-based interactome shows STAT3 as the busiest hub, STAT1 as a frequent antagonist, and points to cytoplasmic nodes for JAK/STAT-targeted therapy ideas.
Study at a glance
- Design
- Computational / modelling — IID 2018 literature-curated STAT PPI interactomes filtered by disease/tissue expression context and visualized with NAViGaTOR
- N
- Network counts of STAT partners (e.g., STAT3 n=166 proteins) rather than a patient cohort N
- Population
- Curated human STAT protein–protein interactions across major cancer contexts
- Outcome
- Member-specific STAT interactomes and proposed targeting points in oncogenic JAK/STAT signaling
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
STAT3 had the largest diversity (166 partners) vs STAT1 (81); STAT3/5 emerge as pleiotropic oncogenes while STAT1 often counters STAT3; EGFR/ESR1 interplay and cytoplasmic hubs inform targeting hypotheses.
Methodology
Using IID 2018 PPIs (stringent multi-evidence + expression context), the authors built global and cancer-specific STAT interactomes and mapped them with NAViGaTOR, integrating literature on STAT-linked diseases.
Limitations
Not a clinical drug trial; missing edges may reflect study bias, and network centrality ≠ proven drug efficacy.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.
Related papers in this topic
Same topic cluster — not a recommendation engine.